1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,140 | 7,200 | 30.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| Mi | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-034 (GPRC5D/CD3 BISPECIFIC T-CELL ENGAGER, TCE) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA | 2 | HKEx | ||
| 22.01. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT ORPHAN DRUG DESIGNATION (ODD) OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) BY THE EUROPEAN ... | - | HKEx | ||
| 16.01. | Global News: Global Development Accelerates: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Granted Fast Track Designation by FDA | 451 | Newsfile | Nanjing, China--(Newsfile Corp. - January 15, 2026) - Nanjing Leads Biolabs Co., Ltd. (HKE: 9887) ("Leads Biolabs" or the "Company") today announced that Opamtistomig (LBL-024), its core investigational... ► Artikel lesen | |
| 14.01. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT- LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA | 2 | HKEx | ||
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 3 | HKEx | ||
| 31.12.25 | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 23.12.25 | Leads Biolabs and Dianthus dose first subject in LBL-047 trial | 2 | Investing.com | ||
| 23.12.25 | Dianthus Therapeutics, Inc.: Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) | 174 | GlobeNewswire (Europe) | LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress... ► Artikel lesen | |
| 23.12.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-024 DOSED FIRST PATIENT IN PHASE IB/II TRIAL FOR PLATINUM-RESISTANT OVARIAN CANCER | 2 | HKEx | ||
| 23.12.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 DOSED FIRST SUBJECT IN PHASE I TRIAL | 1 | HKEx | ||
| 17.12.25 | LEADS BIOLABS-B (09887): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 17.12.25 | LEADS BIOLABS-B (09887): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 17, 2025 | - | HKEx | ||
| 15.12.25 | LEADS BIOLABS-B (09887): INSIDE INFORMATION - PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION PROGRAM BY THE COMPANY | 1 | HKEx | ||
| 01.12.25 | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 RECEIVED IND APPROVAL FROM NMPA | 1 | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): THE H SHARE AWARD SCHEME | - | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): PROXY FORM FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON WEDNESDAY, DECEMBER 17, 2025 | 2 | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 28.11.25 | LEADS BIOLABS-B (09887): (1) PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME; (2) PROPOSED AUTHORIZATION TO THE BOARD OF DIRECTORS AND/OR THE DELEGATEE ... | - | HKEx | ||
| 27.11.25 | LEADS BIOLABS-B (09887): ANNOUNCEMENT BOOK CLOSURE PERIOD FOR EXTRAORDINARY GENERAL MEETING | - | HKEx |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,620 | +0,64 % | QIAGEN: Wochengewinner im DAX - Analyse der KW 4 | ||
| PRAXIS PRECISION MEDICINES | 314,30 | -0,12 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| NUVALENT | 102,89 | +0,45 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,520 | -6,03 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,290 | -3,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,720 | -1,30 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,520 | -0,92 % | How Harmony Biosciences Can Prove Its Skeptics Wrong | ||
| APOGEE THERAPEUTICS | 65,42 | -6,52 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| BIONTECH | 95,80 | -0,21 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| ERASCA | 10,525 | +2,09 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| STRUCTURE THERAPEUTICS | 88,44 | +1,48 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| AVIDITY BIOSCIENCES | 72,58 | +0,03 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARVINAS | 13,380 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 31,110 | -2,75 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,460 | -6,10 % | Summit Therapeutics: FDA akzeptiert Zulassungsantrag für Lungenkrebsmedikament Ivonescimab |
NANJING LEADS BIOLABS CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,070 (-0,98 %) liegt der Kurs bei 7,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.